Clinical trial NCT05632861: HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)
Official title: Efficacy and Safety of HuHuangLianzonggan Capsule in Subjects With Nonalcoholic steatoHEPAtitis: a Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 tRial(HHL-HEPAR)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: NASH
Lead sponsor: Tasly Pharmaceutical Group Co., Ltd
Sponsor class: INDUSTRY
First posted: 2022-12-01
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the efficacy and safety and the best effective dose of HuHuangLianzonggan capsule in subjects with nonalcoholic steatohepatitis.


Eligibility criteria: Inclusion Criteria:

1. Males and females between 18-75 years of age inclusive(including boundary values).
2. Must have had a liver biopsy proven NASH within 6 months or in screening test. The following two requirements must be met at the same time: ① a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components: Steatosis≥1, Lobular inflammation≥1, Ballooning degeneration≥1;② fibrosis stage 1 to 3.
3. Must have confirmation of ≥ 8% liver fat content on magnetic resonance imaging- proton density fat fraction (MRI-PDFF) at screening.
4. No alcohol consumption or history of excessive alcohol consumption: less than 210 g of ethanol per week for men and 140 g for women in the past 12 months.
5. Patients who are taking chronic drugs(including but not limited to antihypertensive drugs, antiatherogenic drugs, oral hypoglycemic drugs, insulin) need to have a steady dose for at least 3 months before liver biopsy.
6. Weight was stable(the change is no more than 5%) during the 6 months prior to Screening.
7. No attempt to change lifestyle (diet and/or exercise) during the 3 months prior to Screening.
8. Ability to understand the requirements of the study and willingness to provide written informed consent.
9. Have no pregnancy program and take effective contraceptive measures voluntarily.
10. Abide by the experimental protocol and cooperate with the data collection according to the researcher's judgment.

Exclusion Criteria:

1. Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD) administered for at least 2 weeks within 12 months prior to qualifying liver biopsy (e.g. valproic acid, tamoxifen, methotrexate, amiodarone, oral corticosteroids, \>5 mg/day of prednisone equivalent \[one short (\<2 weeks) course of oral corticosteroids, more than 3 months before the liver biopsy is allowed\], or oestrogens \[at doses greater than those used for contraception or hormone replacement\]).
2. Documented causes of fatty liver disease other than NASH including, but not restricted to: HCV-associated fatty liver (genotype 3), hepatolenticular degeneration, autoimmune hepatitis, total parenteral nutrition, abetalipoproteinemia, lipoatrophy , Coeliac disease, Primary sclerosing cholangitis, Alpha-1-antitrypsin deficiency, Drug-induced liver disease.
3. Model for End-stage Liver Disease (MELD) score \>12.
4. Histologically documented liver cirrhosis (fibrosis stage F4), history or current diagnosis of hepatocellular carcinoma HCC.
5. History of or planned liver transplant.
6. Viral hepatitis：Positive hepatitis A antibody，Positive hepatitis D antibody，Positive hepatitis E antibody，Positive hepatitis B surface antigen (HBsAg) ，Positive hepatitis C antibody.
7. Abnormal liver function as defined by Screening central laboratory evaluation of any of the following: ALT or AST \>5 × ULN; Alkaline phosphatase (ALP) \>2 × ULN; albumin below the lower limit of the normal range; total bilirubin level \>1.5 × ULN (patients with a documented history of Gilbert's syndrome can be enrolled if the direct bilirubin is within normal reference range).
8. In patients who are not anticoagulated, INR ≥ 1.3 times ULN or other evidence of impaired coagulation.
9. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value \<30 mL/min/1.73 m2.
10. Patient currently receiving any approved treatment for NASH.
11. HbA1c ≥9% or fasting blood-glucose\>13.9 mmol/L at Screening.
12. Diabetes mellitus other than type 2 (e.g. type 1, diabetes caused by drugs or chemicals, and immune-mediated diabetes).
13. Those who are underweight, of normal weight, or severely obese, i.e BMI\<23 kg/m2 or BMI≥40 kg/m2.
14. Bariatric surgery or tumor surgery are not allowed within 5 years of the qualifying liver biopsy.
15. Uncontrolled hypertension (values ≥160/100 mm Hg) or hypotension（values \<80/50 mmHg）.
16. Acute vascular events including ACS, stroke, peripheral vascular disease worsened, or any vascular/cardiac surgery within the 6 months prior to Screening.
17. Concomitant mental illness and poor condition control, which affects the signing of informed consent or presentation of adverse events.
18. Do not have a liver biopsy within the 6 months prior to Screening and refuse to take liver biopsy at Screening.
19. Allergic constitution, or allergic to the test drug or its ingredients.
20. Women who are pregnant or lactating.
21. Participate in clinical trials of other drugs within 3 months before screening.
22. The researchers did not consider it appropriate to participate in this study.

Primary outcomes:
measure: Change from baseline in hepatic fat fraction assessed by MRI-PDFF at week 12.
timeFrame: Week 12
measure: Proportion of subjects with ≥ 30% relative fat reduction on MRI-PDFF at week 12.
timeFrame: Week 12
Secondary outcomes:
measure: Change from baseline in weight at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in Body Mass Index (BMI) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in waist hip rate at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in fasting blood glucose at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in 2 hours postprandial hyperglycemia at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in homeostasis model assessment-insulin resistance (HOMA-IR) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in Total Cholestrol (TC) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in triglyceride (TG) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in Low Density Lipoprotein Cholesterol (LDL-C) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in High Density Lipoprotein Cholesterol (HDL-C) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in Glycosylated hemoglobin A1c (HbA1c) at week 12.
timeFrame: Week 12
measure: Change from baseline in Alanine aminotransferase (ALT) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in Aspartate aminotransferase (AST) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in total bilirubin (TBil) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in Cytokeratin18 (CK-18) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in N-terminal type Ⅲ collagen propeptide (Pro-C3) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in Fibrosis 4 score at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in Chronic Liver Disease-NAFLD questionnaire (CLDQ-NAFLD) at week 4, 12.
timeFrame: Week 4, 12
measure: Change from baseline in ferritin at week 4, 12.
timeFrame: Week 4, 12
Other outcomes:
Locations:
city: Hefei
country: China
facility: Anhui Provincial Hospital
state: Anhui
city: Hefei
country: China
facility: The Second Hospital of Anhui Medical University
state: Anhui
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
city: Fuzhou
country: China
facility: The first affiliated hospital of Fujian medical university
state: Fujian
city: Guangzhou
country: China
facility: Nanfang Hospital, Southern Medical University
state: Guangdong
city: Shenzhen
country: China
facility: The Third People's Hospital of Shenzhen
state: Guangdong
city: Luoyang
country: China
facility: The First Affiliated Hospital of Henan University of Science and Technology
state: Henan
city: Wuhan
country: China
facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology
state: Hubei
city: Lianyungang
country: China
facility: The First People's Hospital of Lianyungang
state: Jiangsu
city: Nanjing
country: China
facility: The Affiliated Hospital of Nanjing University medical school，Nanjing Drum Tower Hospital
state: Jiangsu
city: Nanjing
country: China
facility: The Second Hospital of Nanjing
state: Jiangsu
city: Xuzhou
country: China
facility: The Affiliated Hospital of Xuzhou Medical University
state: Jiangsu
city: Yinchuan
country: China
facility: General Hospital of Ningxia Medical University
state: Ningxia
city: Chengdu
country: China
facility: Sichuan Provincial People's Hospital
state: Sichuan
city: Tianjin
country: China
facility: Tianjin Second People's Hospital
state: Tianjin
city: Hangzhou
country: China
facility: The Affiliated Hospital of Hangzhou Normal University
state: Zhejiang
city: Ningbo
country: China
facility: Ningbo Huamei Hospital, University of Chinese Academy of Sciences
state: Zhejiang
city: Ningbo
country: China
facility: Ningbo Medical Center Lihuili Hospital
state: Zhejiang
city: Taizhou
country: China
facility: Taizhou Municipal Hospital
state: Zhejiang
city: Wenzhou
country: China
facility: Rui'an People's Hospital
state: Zhejiang
Study officials:
References: